Overview: BCR-ABL Quantitative TestIntroduction: The BCR-ABL Quantitative Test monitors minimal residual disease in leukemia by measuring BCR-ABL gene levels, helping track treatment response. Aligned with 2023 NCCN guidelines, it uses PCR for high sensitivity, aiding in cancer screening. This test is critical for guiding treatment adjustments, monitoring leukemia, and improving outcomes in molecular pathology for patients with CML.
Other Names: BCR-ABL Quantitative Assay, CML Monitoring Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: BCR-ABL monitoring began in the 1990s with quantitative PCR. By the 2000s, real-time PCR improved sensitivity for minimal residual disease detection.
Purpose: Monitors CML treatment response, guides therapy adjustments, and tracks minimal residual disease in patients with leukemia.
Test Parameters: 1. BCR-ABL Gene Rearrangement
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva at any time. Report treatment history or symptoms like fatigue, and list medications like tyrosine kinase inhibitors.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document leukemia treatment history, symptoms, or family history of blood cancers. Include current medications, especially tyrosine kinase inhibitors.
Consent: Written consent required, detailing the tests purpose, implications for treatment monitoring, and potential need for therapy adjustments.
Procedural Considerations: Uses real-time PCR to quantify BCR-ABL gene levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade RNA. Low sample quality may affect PCR sensitivity.
Clinical Significance: Elevated BCR-ABL levels indicate treatment resistance, prompting therapy changes. Low levels suggest remission, guiding monitoring.
Specialist Consultation: Consult a hematologist for result interpretation. An oncologist referral is advised for treatment planning.
Additional Supporting Tests: BCR-ABL qualitative test, bone marrow biopsy, or FISH to assess disease status or confirm CML.
Test Limitations: False negatives may occur with low-level disease. Results require clinical correlation with treatment history.
References: NCCN CML Guidelines, 2023; Blood, Baccarani M, 2022.
